Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Mesoblast Ltd Ads (MESO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 624,347
  • Shares Outstanding, K 94,170
  • Annual Sales, $ 17,340 K
  • Annual Income, $ -35,290 K
  • 36-Month Beta 2.03
  • Price/Sales 34.92
  • Price/Cash Flow N/A
  • Price/Book 1.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.23
  • Number of Estimates 2
  • High Estimate -0.22
  • Low Estimate -0.25
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -187.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.70 +19.30%
on 09/11/18
6.80 unch
on 09/21/18
+0.94 (+16.04%)
since 08/21/18
3-Month
5.37 +26.63%
on 06/29/18
7.27 -6.46%
on 07/30/18
+0.74 (+12.21%)
since 06/21/18
52-Week
4.74 +43.46%
on 02/13/18
7.79 -12.71%
on 03/01/18
+1.34 (+24.54%)
since 09/21/17

Most Recent Stories

More News
Children Treated With Remestemcel-L Continue to Have Strong Survival Outcomes at Six Months in Mesoblast's Phase 3 Trial for Acute Graft Versus Host Disease

Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced continued strong survival outcomes through Day 180 in children with steroid refractory acute Graft Versus Host Disease (aGVHD) treated with Mesoblast's...

MESO : 6.96 (+4.98%)
Tasly Pharmaceutical Group Receives All Necessary Approvals for Transaction With Mesoblast

Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that Tasly Pharmaceutical Group has successfully obtained all necessary approvals, including the Safe Administration of Foreign Exchange, required...

MESO : 6.96 (+4.98%)
Mesoblast Reports Fourth Quarter and Full-Year 2018 Financial Results and Operational Highlights

Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today reported strong financial results and provided operational highlights for the fourth quarter and full-year ended June 30, 2018 (FY2018).

MESO : 6.96 (+4.98%)
Leading Commercial and Transactional Healthcare Executive Shawn Cline Tomasello Joins Mesoblast Board

Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that Shawn Cline Tomasello has joined its Board of Directors. With more than 30 years' experience in the pharmaceutical and biotech industries,...

MESO : 6.96 (+4.98%)
KITE : 179.99 (+0.11%)
MSB : 27.76 (-0.14%)
Mesoblast Enters Into US$50M Financing with Novaquest Capital for Commercial Readiness of Remestemcel-l in the Treatment of Acute Graft Versus Host Disease

Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced a US$50 million financing from NovaQuest Capital Management, L.L.C. (NovaQuest) for the continued development and commercialization of its allogeneic...

MESO : 6.96 (+4.98%)
MSB : 27.76 (-0.14%)
Key Day 100 Survival Outcomes of Phase 3 Trial for Acute Graft Versus Host Disease Presented at 2018 ISSCR Annual Meeting

Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced key Day 100 survival outcomes of its Phase 3 trial for remestemcel-L, an allogeneic mesenchymal stem cell product candidate, in children with steroid...

MESO : 6.96 (+4.98%)
MSB : 27.76 (-0.14%)
U.S. Healthcare Leader Joseph R. Swedish Joins Mesoblast Board

Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that Joseph R. Swedish has joined its Board of Directors. Mr. Swedish has more than two decades of healthcare leadership experience as the CEO...

MESO : 6.96 (+4.98%)
ANTM : 273.05 (-0.39%)
MSB : 27.76 (-0.14%)
Mesoblast Phase 3 Trial Results for Acute Graft Versus Host Disease Presented at 2018 International Society for Cell and Gene Therapy Annual Meeting

Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that results of the Phase 3 trial evaluating its product candidate MSC-100-IV (remestemcel-L) in children with steroid-refractory acute Graft versus...

MESO : 6.96 (+4.98%)
MSB : 27.76 (-0.14%)
Mesoblast Cell Therapies Featured at Vatican International Healthcare Conference

Mesoblast's proprietary allogeneic cell technology platform was featured at the Unite to Cure Fourth International Vatican Conference on global healthcare initiatives held in Vatican City from April 26-28,...

MESO : 6.96 (+4.98%)
MSB : 27.76 (-0.14%)
Wired News - Mesoblast Announced Updated Data from Phase-3 and Phase-2b Clinical Trials of MPC-150-IM in Patients with Chronic Heart Failure

Stock Monitor: Caladrius Biosciences Post Earnings Reporting

MESO : 6.96 (+4.98%)
CLBS : 6.68 (+2.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade MESO with:

Business Summary

Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's...

See More

Key Turning Points

2nd Resistance Point 6.88
1st Resistance Point 6.76
Last Price 6.96
1st Support Level 6.50
2nd Support Level 6.36

See More

52-Week High 7.79
Last Price 6.96
Fibonacci 61.8% 6.62
Fibonacci 50% 6.26
Fibonacci 38.2% 5.91
52-Week Low 4.74

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar